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Therapeutic options for recto-vaginal ﬁstula in the setting of Crohn’s disease are limited and many data are available in the
literature. The manuscript describes the history of a patient who has been the pioneer of our Clinical Trials in treating this disease
inﬁstulizing Crohn’sdisease environment. We believe it is theﬁrst timethat apatient with this disease has been treated by adipose-
derived stem cells in allogeneic form. The conclusion of our study with Mary is that the use of mesenchymal stem cells derived
from adipose tissue is secure, either in autologous or allogeneic form. Furthermore, we have proved that if we use multi-dose
and multiple applications on a patient, it does not produce any adverse eﬀect, which conﬁrms us the safety of using these cells in
patients at least in the ﬁstulizing Crohn’s disease environment
1.Introduction
HumanAdipose-DerivedStemCellsemergeaskeyregulators
of immune/inﬂammatory responses in vivo and as attractive
candidates for cell-based therapies to treat IBD, sepsis and
hence to improve healing [1]. To illustrate this sentence we
believe that Mary’s story (not her real name) could be a good
IBD clinical picture that oﬀers a glimmer of hope.
The management of rectovaginal ﬁstulas in patients
with Crohn’s disease continues to be extremely challenging
and, indeed, somewhat frustrating [2]. Such ﬁstulas are a
very distressing complication that signiﬁcantly reduces the
quality of life of aﬀected women. Various therapies have
been proposed, such as advancement ﬂap plasty [3], Martius
plasty [4], gracilis transposition [5], and proctectomy and
deﬁnitive colostomy, when a cure is impossible. It is also
important to consider the incontinence rate associated to
these procedures. In a study of 310 patients who underwent
surgery (ﬁstulotomy and rectal advancement ﬂap) for anal
incontinence, van Kooperen et al. [6] reported soiling
in 40%, but there were no reports of anal incontinence
associated with ASCs implantation. Recent improvements
in medical treatment (e.g., inﬂiximab) and expert surgical
management have decreased the need for proctectomy.
However, recurrence has a major negative impact on the
quality of life. The suboptimal quality of perianal tissues
that are aﬀected by Crohn’s disease is probably the origin of
t h ef a i l u r et oh e a l[ 4]. Long-term therapy with inﬂiximab
(as would be used in maintenance regimens) is generally
well tolerated although clinicians are urged to be particularly
vigilant for rare but serious adverse events such as serum
sickness-like reaction, opportunistic infection and sepsis,
and autoimmune disorders [7].
2. Case Presentation
In 2002, we decided to test a cell-based therapeutic protocol
on a young woman with Crohn’s disease and recurrent
intractable rectovaginal ﬁstulas [8]. Autologous adipose-
derived stem cells (ASCs) were chosen as the cell source
becausetheyareeasilyharvestedusingliposuction.Although
Crohn’s disease is the worst scenario in treatment of recto-
vaginal ﬁstula, we observed satisfactory healing without fecal
incontinence.Inviewofthesuccessfuloutcome,apilotstudy
was started [9] and Mary, a 34-year-old woman diagnosed2 Case Reports in Medicine
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of Crohn’s disease ten years before, was included. At the
time, Mary had four enterocutaneous and one rectovaginal
ﬁstula. After liposuctions, hASCs were isolated, processed
and expanded. The enterocutaneous ﬁstulas healed after
injection of hASCs according to our protocol (Figure 1). The
rectovaginal ﬁstula was also treated using hASCs (Figure 2),
but complete healing was not achieved.
Later, in 2004, we conducted a phase II clinical triala [10]
that aimed to test the eﬀectiveness of hASCs (investigational
drug code: Cx401b) in the treatment of complex perianal
ﬁstula and Mary was once again included but assigned to
the control group. A total of 8 women with rectovaginal
ﬁstulas participated (4 with Crohn’s disease). Four women
were treated with stem cells (treatment group) and complete
closure was achieved in 3. The other 4 women—Mary
included—were treated with ﬁbrin glue (control group)
with no healing in any of the cases. Mary’s ﬁstula therefore
remained unhealed.
During 2006 we designed two phase III clinical trials
that aimed to deﬁnitively assess the eﬃcacy of autologous
ASCs in complex perianal ﬁstula and these are currently
underway. However, women with rectovaginal ﬁstula were
excludedtominimizeclinicalvariabilityandsoMarywasnot
eligible. We decided to treat her ﬁstula by compassionate use
according to the European regulatory laws and the Spanish
Medicines Agency guidelines. After obtaining regulatory
permission, a new liposuction procedure was performed
and the protocol for Cx401 therapy started. Unfortunately,
bacterial contamination occurred during the cell expansion
process and treatment was aborted. To avoid further failure,
after carefully consideration of the regulatory implications,
we proposed a new attempt using, this time, allogenic
ASCs. We obtained and processed adipose material from a
donor and the ASCs obtained (investigational drug code:
Cx601) were used to treat Mary’s rectovaginal ﬁstula. To our
knowledge, this is the ﬁrst time that allogenic ASCs have
been used in humans. No rejection or adverse events were
observed, but the ﬁstula remained open. Nevertheless a great
improvement was appreciated and a new cell injection is
schedule.
3. Discussion
This is Mary‘s clinical picture so far. During her life, Mary
will probably suﬀer further outbreaks of Crohn’s disease
that might produce new ﬁstulas, but these could perhaps be
treated once again with stem cells in an attempt to exploit
de capacities of Adipose-Derived Stem Cells as regulators of
inﬂammatory and healing responses.
References
[1] E. Gonzalez-Rey, P. Anderson, M. A. Gonz´ alez, L. Rico, D.
B¨ uscher, and M. Delgado, “Human adult stem cells derived
from adipose tissue protect against experimental colitis and
sepsis,” Gut, vol. 58, no. 7, pp. 929–939, 2009.
[2] C. Levy and W. J. Tremaine, “Management of internal ﬁstulas
in Crohn’s disease,” Inﬂammatory Bowel Diseases, vol. 8, no. 2,
pp. 106–111, 2002.
[3] F. Penninckx, A. D’Hoore, and L. Filez, “Advancement ﬂap
plasty for the closure of anal and recto-vaginal ﬁstulas in
Crohn’s disease,” Acta Gastro-Enterologica Belgica, vol. 64, no.
2, pp. 223–226, 2001.
[4] R. Reid and D. G. Gallup, “Local and distant skin ﬂaps in
the reconstruction of vulvar deformities,” American Journal
of Obstetrics and Gynecology, vol. 177, no. 6, pp. 1372–1384,
1997.
[5] J. Rius, A. Nessim, J. J. Nogueras, and S. D. Wexner, “Gracilis
transposition in complicated perianal ﬁstula and unhealed
perineal wounds in Crohn’s disease,” European Journal of
Surgery, vol. 166, no. 3, pp. 218–222, 2000.
[6] P. J. van Koperen, J. Wind, W. A. Bemelman, R. Bakx, J. B.
Reitsma, and J. F. M. Slors, “Long-term functional outcome
and risk factors for recurrence after surgical treatment for low
and high perianal ﬁstulas of cryptoglandular origin,” Diseases
of the Colon and Rectum, vol. 51, no. 10, pp. 1475–1481, 2008.
[7] M. A. Parsi and B. A. Lashner, “Safety of inﬂiximab: primum
non nocere. The safety proﬁle of inﬂiximab in patients with
Crohn’s disease: the Mayo Clinic experience in 500 patients,”
Inﬂammatory Bowel Diseases, vol. 10, pp. 486–487, 2004.
[8] D.Garc´ ıa-Olmo,M.Garc´ ıa-Arranz,L.G.Garc´ ıa,etal.,“Autol-
ogous stem cell transplantation for treatment of rectovaginal
ﬁstula in perinatal Crohn’s disease: a new cell-based therapy,”
International Journal of Colorectal Disease,v o l .1 8 ,n o .5 ,p p .
451–454, 2003.Case Reports in Medicine 3
[9] D. Garc´ ıa-Olmo, M. Garc´ ıa-Arranz, D. Herreros, I. Pascual, C.
Peiro, and J. A. Rodr´ ıguez-Montes, “A phase I clinical trial of
the treatment of crohn’s ﬁstula by adipose mesenchymal stem
cell transplantation,” Diseases of the Colon and Rectum, vol. 48,
no. 7, pp. 1416–1423, 2005.
[10] D. Garcia-Olmo, D. Herreros, I. Pascual, et al., “Expanded
adipose-derived stem cells for the treatment of complex
perianal ﬁstula: a phase II clinical trial,” Diseases of the Colon
and Rectum, vol. 52, no. 1, pp. 79–86, 2009.